| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
Revenue  | 523 | 571 | 558 | 583 | 745 | 845 | 826 | 820 | 1,029 | 1,330 | 1,652 |
| Expenses | 529 | 547 | 507 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,493 |
| EBITDA | -6 | 23 | 51 | 59 | 88 | 134 | 148 | 101 | 191 | 219 | 159 |
| Operating Profit % | -2 % | 3 % | 7 % | 8 % | 10 % | 15 % | 17 % | 11 % | 16 % | 14 % | 8 % |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 26 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 132 |
| Tax | 0 | 1 | 15 | 18 | 18 | 42 | 34 | 21 | 35 | 58 | 53 |
| Net Profit | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 97 |
| EPS in ₹ | -8.34 | 2.10 | 8.00 | 10.40 | 21.80 | 28.90 | 37.30 | 24.60 | 39.70 | 64.60 | 39.80 |
AstraZeneca Pharma
8,416.35
-64.10
(-0.76%)
Market Cap
21,201.10 Cr
EPS
64.60
PE Ratio
125.81
Dividend Yield
0.28 %
Industry
Healthcare52 Week High
9,059.05
52 Week Low
4,800.15
PB Ratio
31.04
Debt to Equity
0.01
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
29.27 %
Net Income Growth
62.64 %
Cash Flow Change
-52.19 %
ROE
34.50 %
ROCE
36.57 %
EBITDA Margin (Avg.)
-11.30 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 412 | 403 | 416 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 |
| Fixed Assets | 101 | 97 | 87 | 76 | 75 | 72 | 81 | 75 | 69 | 67 |
| Current Assets | 263 | 267 | 252 | 321 | 405 | 542 | 619 | 706 | 836 | 933 |
| Capital Work in Progress | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 |
| Total Liabilities | 412 | 403 | 416 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 |
| Current Liabilities | 260 | 234 | 190 | 207 | 259 | 327 | 304 | 333 | 384 | 357 |
| Non Current Liabilities | 1 | 13 | 2 | 7 | 2 | 15 | 15 | 13 | 12 | 9 |
| Total Equity | 151 | 156 | 223 | 247 | 301 | 364 | 456 | 511 | 589 | 712 |
| Reserve & Surplus | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 |
| Investing Activities | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 |
| Operating Activities | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 |
| Financing Activities | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -10 | -25 | -44 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.69 % | 0.00 % | 2.74 % | 2.79 % | 2.90 % | 2.93 % |
| DIIs | 0.83 % | 0.94 % | 0.96 % | 1.00 % | 1.02 % | 1.10 % | 1.12 % | 1.44 % | 1.42 % | 1.93 % | 2.43 % | 2.75 % | 3.78 % | 5.01 % | 5.10 % | 5.22 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.53 % | 19.72 % | 19.69 % | 19.44 % | 19.06 % | 18.62 % | 18.54 % | 18.56 % | 18.46 % | 18.12 % | 17.44 % | 17.09 % | 16.33 % | 15.00 % | 14.77 % | 14.62 % |
| Others | 4.64 % | 4.34 % | 4.34 % | 4.57 % | 4.92 % | 5.28 % | 5.34 % | 5.01 % | 5.12 % | 4.95 % | 2.44 % | 5.15 % | 2.15 % | 2.20 % | 2.23 % | 2.24 % |
| No of Share Holders | 0 | 63,753 | 68,077 | 66,444 | 62,183 | 57,760 | 53,980 | 49,085 | 42,146 | 38,946 | 32,380 | 29,032 | 29,418 | 27,169 | 27,615 | 27,322 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 1 | 2 | 10 | 16 | 24 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | 0.31 | 0.3 | 0.29 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Closure of Trading Window
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements)
Regulation 2015
Integrated Filing (Financial)
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Newspaper Publication
Outcome Of The Board Meeting Held On Tuesday February 11 2025
Press Release
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday February 11 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday February 11 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Closure of Trading Window
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Launch Of Budesonide Ph. Eur 160Mcg+ Glycopyrronium Ph. Eur 7.2Mcg+Formoterol Fumarate Dihydrate Ph. Eur 5Mcg Inhalation Preparations (BreztriAerosphere)
Announcement under Regulation 30 (LODR)-Newspaper Publication
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Additional Director (Non-Executive)
Outcome Of The Board Meeting Held On Wednesday, November 13, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Wednesday, November 13, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management Personnel
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Board Meeting Outcome for Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Technical Indicators
RSI(14)
Neutral 74.39
ATR(14)
Less Volatile 357.86
STOCH(9,6)
Neutral 71.03
STOCH RSI(14)
Overbought 90.69
MACD(12,26)
Bullish 102.90
ADX(14)
Strong Trend 40.44
UO(9)
Bearish 41.10
ROC(12)
Uptrend But Slowing Down 12.72
WillR(14)
Neutral -34.22
About AstraZeneca Pharma
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for heart failure and chronic kidney disease, Imfinzi for biliary tract carcinoma, Lynparza for breast cancer, and oral antidiabetic drugs like Onglyza and Kombiglyze. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is indirectly owned by AstraZeneca PLC, United Kingdom. The company has manufacturing facilities in Bangalore and has expanded its R&D presence in India.
Website
Chairperson NameNarayan K Seshadri
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
